Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (American Society of Clinical Oncology) Annual Meeting.

In ROSELLA, patients treated with Lifyorli combined with nab-paclitaxel experienced a 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio (HR): 0.65; p-value: 0.0004), with a median overall survival of 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone. No biomarker testing was required.

Patients in all of ROSELLA’s prespecified subgroups experienced meaningful survival benefits. The data presented at ASCO 2026 describe the overall survival benefit in patients whose treatment included a taxane-free interval of 6 months or less (HR: 0.60) and in those who received a taxane in their most recent treatment regimen (HR: 0.67).

“Relacorilant stands to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, because of the consistent overall survival observed across all patient subgroups, including those with poor prognostic features and regardless of prior taxane exposure, without the need for biomarker selection," said Lucy Gilbert, M.D., Director of Gynecologic Oncology at McGill University Health Centre, Chair of Oncology, McGill University, Montreal.

"The results of the ROSELLA study clearly demonstrate that antagonizing the effects of cortisol at the glucocorticoid receptor (GR) can deliver improved survival outcomes in patients with a challenging-to-treat cancer,” said Bill Guyer, PharmD, Corcept's Chief Development Officer. “They support our long-standing belief in the potential of our GR antagonists to treat patients with many tumor types. We are working to advance GR research in many different treatment settings, including platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers.”

Schreibe Deinen Kommentar